Appendix 3Y - Dr Daniel Tillett
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity
Race Oncology Limited
ABN
61 149 318 749
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Daniel Tillett
Date of last notice
16 January 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Date of change
7 February 2023
No. of securities held prior
to change
13,685,282 – fully paid ordinary shares
2,307,925 – fully paid ordinary shares subject to voluntary
escrow until 14/11/2023
2,000,000 – options exercisable at $2.65, expiring 29/11/2025
and subject to vesting conditions
Class
Fully paid ordinary shares
Number acquired
6,793 fully paid ordinary shares
Number disposed
-
Value/Consideration
includes brokerage/gst
$13,044.43
Note: Provide details of the circumstances
giving rise to the relevant interest.
Note: If consideration is non-cash, provide
details and estimated valuation
+ See chapter 19 for defined terms.
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
No. of securities held after
change
13,692,075 – fully paid ordinary shares
2,307,925 – fully paid ordinary shares subject to voluntary
escrow until 14/11/2023
2,000,000 – options exercisable at $2.65, expiring 29/11/2025
and subject to vesting conditions
Nature of change
On-market -purchases
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to N/A
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: If consideration is non-cash, provide details and an
estimated valuation
Part 3 – +Closed period
Were the interests in the securities or contracts detailed No
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade N/A
to proceed during this period?
If prior written clearance was provided, on what date was this N/A
provided?
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
Share your feedback
Discover